Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 1491150-22-1, 5-Bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide

  • 1491150-22-1

  • C13H7BrCl2F2N2O2

  • 412

  • 1.745±0.06

  • Philadelphia chromosome-positive chronic myeloid leukemia

  • Asciminib

  • 5/14/2040 (Asciminib)

  • ABL/BCR-ABL1 tyrosine kinase



As a novel BCR-ABL inhibitor, Asciminib offers a highly targeted therapy that tackles CML with remarkable efficacy and improved safety profile. With its innovative mechanism of action and potential to overcome resistance mutations, Asciminib represents a significant advancement in the management of CML. By incorporating Asciminib into your pharmaceutical portfolio, you can empower patients with this innovative and life-changing treatment option. Join the fight against CML with Asciminib and make a lasting impact on patient care.